bionorthTX debuts region’s growing life sciences industry at BIO 2016

bionorthTX will use the upcoming Biotechnology Innovation Organization’s (BIO) 2016 International Convention in San Francisco, 6-9 June to spotlight the region’s burgeoning life sciences industry and world-class universities.
Founded in 2014 to promote North Texas’s life sciences and healthcare innovation and industry development, bionorthTX will showcase the region’s companies and research institutions to more than 15,000 biotech and pharma leaders from 69 countries.
“To outsiders our region may be known more for the financial market, software, oil & gas and the stockyards than life science and healthcare innovation,” said bionorthTX co-founder and COO Kay Tieman. “Participating in the BIO annual convention will give us an opportunity to show the world’s biotech and pharma professionals we are a leading center of health care and life sciences industry development, which should also drive public and private capital to our members.”
North Texas is home to 1,000 life sciences related companies with more than 26,000 employees focused on therapeutics, diagnostics, devices, clinical research, contract manufacturing and health care IT. The region includes a range of companies from multinational corporations such as Abbot Laboratories, Alcon, Celanese Chemicals, Covance Clinical Research, Essilor, Galderma Laboratories, McKesson Corp., and Smith & Nephew, to emerging companies like Neos Therapeutics, Reata Pharmaceuticals, ZS Pharma and Thermi, to startups. In addition, a critical element of the foundation for life sciences industry development is a strong network of collaborative universities. North Texas’s academic institutions, global leaders in life sciences research, include University of Texas (UT) Southwestern Medical Center, UT’s Arlington and Dallas campuses, along with Baylor Scott & White Health and Research Institute and the University of North Texas Health Science Center in Fort Worth.
“Among our major initiatives,” Tieman said, “is our 2nd annual iC3 Life Science Summit, which last year brought 275 stakeholders together to discuss Innovation, Collaboration, Capital formation and Commercialization (iC3) in North Texas. It will be held on October 26th at UT Arlington and we anticipate 350-400 in attendance.”
Examples of the region’s growing health care industry include the recent expansion of Galderma’s $22 million research and development center, expected to add up to 350 employees, and McKesson’s opening of a new distribution center with 950 employees.
Thermi, a company developing thermistor-regulated energy solutions for aesthetics, dermatology and women's health, also is expanding following its acquisition by Barcelona-based Almirall for $88 million; and Neos Therapeutics, an emerging company developing treatments for attention deficit hyperactivity disorder, held a successful initial public offering in 2015.
“We have an exciting story to tell about North Texas’s vibrant health care and life sciences industries,” Tieman said. “This is a primary objective for bionorthTX and attending BIO 2016 is just a first step.”
Related News
-
News Women in Pharma: Career Design for Women
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News CPHI Podcast Series: Packaging expert perspectives at Pharmapack 2025
This month's podcast episode sounds a little different, covering the latest event in Paris – Pharmapack 2025. Digital Editor Lucy Chard speaks to several experts direct from the floor of the show, bringing you right in on the action.&nbs... -
News Closing 2024 with Editors' picks of top articles from the past year
Coming to the end of 2024 and it’s certainly been a busy year, for CPHI and for the rest of the pharmaceutical and healthcare industry. Topics of conversation throughout the last 12 months have been varied, touching on the technical, to the polit... -
News SCHOTT Pharma’s sustainable journey with CPHI
Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. -
News CPHI Podcast Series: Investing in a vision for the future of life sciences
In this episode Lucy Chard is joined by Rajiv Khatau to discuss the importance of looking into new therapeutic areas and some of the more niche areas of pharmaceuticals, and investing in the future of the industry. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance